UroLift® was approved by the FDA in 2013 and provides the patient a minimally invasive approach to treat the enlarged prostate. The procedure uses a series of anchored permanent implants to reshape the prostate and relieves urethral constriction without resecting or vaporizing tissue to allow urine to flow freely through the urethra.
Benign prostatic hyperplasia (BPH): Enlarged prostate gland narrows the urethra, preventing the urine from draining out of the bladder.
A pre-procedure work-up will occur during an outpatient visit(s) This may or may not include the following, which is at the discretion of your urologist.
Based on the size and anatomy of the prostate, treatment options will be discussed with your urology team.
UroLift® can be done if the bladder has some bladder contraction present, the prostate is 80-grams or less, and the hypertrophy of the prostate is bi-lobar, meaning no median lobe. A median lobe means there is growth coming from the bottom of the prostate.
Once all the testing is completed, a plan is created and your options will be discussed with your provider.
UroLift® is done in an outpatient setting. The UroLift® delivery device is passed through the obstructed urethra using cryptoscopic guidance. Most prostate requires 4 to 6 implants. The implants consist of a nitinol capsular tab, a retractable PET suture and a stainless steel urethral end piece. The implants are placed at the 2 and 10 o’clock positions of the prostate to mechanically lift and separate the obstructing tissue. The implantation procedure takes only a few minutes. The entire procedure should take less than one hour.
These are some of the more common side effects that may occur following the procedure:
Check out this treatment comparison chart for more benefits of the UroLift® System.
Join us for a FREE UroLift® education seminar on Thursday, March 27, 2018 at 5:00pm. Learn more.
Our physicians are experienced in treating the complete range of urologic conditions and diseases, from kidney stones and sexual dysfunction to prostate cancer, incontinence and infertility.
Website design by: Legato Healthcare Marketing